Chongqing, September 10, 2020 – 2020 Conference on High Quality Development of Healthcare Industry & the Fifth China Pharmaceutical R&D and Innovation Summit was held
Please reserve for your seat at the below eventbrite link for free. https://www.eventbrite.com/e/novel-therapeutic-targets-in-both-breast-and-kidney-cancers-tickets-119195604261 Hypoxia is associated with resistance towards radiation and chemotherapy. As tumors grow,
Yichang, Hubei, Aug 13, 2020 – A seminar on preclinical R&D strategic cooperation was held between Medicilon. INC (Stock Code: 688202. SH) and Yichang Humanwell
Medicilon will exhibit the ACS Fall 2020 Virtual Meeting & Expo from Aug 17-20. Please visit https://calendly.com/fywang to schedule a 1-on-1 meeting with our VP
On July 20, 2020, DAC Biotech’s new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor.
